Relay Therapeutics (RLAY) Retained Earnings (2020 - 2025)
Historic Retained Earnings for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$2.0 billion.
- Relay Therapeutics' Retained Earnings fell 1764.71% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 1764.71%. This contributed to the annual value of -$1.7 billion for FY2024, which is 2411.2% down from last year.
- Per Relay Therapeutics' latest filing, its Retained Earnings stood at -$2.0 billion for Q3 2025, which was down 1764.71% from -$1.9 billion recorded in Q2 2025.
- Over the past 5 years, Relay Therapeutics' Retained Earnings peaked at -$446.4 million during Q1 2021, and registered a low of -$2.0 billion during Q3 2025.
- Over the past 5 years, Relay Therapeutics' median Retained Earnings value was -$1.3 billion (recorded in 2023), while the average stood at -$1.3 billion.
- Its Retained Earnings has fluctuated over the past 5 years, first crashed by 16538.04% in 2021, then crashed by 1764.71% in 2025.
- Over the past 5 years, Relay Therapeutics' Retained Earnings (Quarter) stood at -$768.1 million in 2021, then plummeted by 37.82% to -$1.1 billion in 2022, then tumbled by 32.3% to -$1.4 billion in 2023, then dropped by 24.11% to -$1.7 billion in 2024, then dropped by 15.06% to -$2.0 billion in 2025.
- Its Retained Earnings stands at -$2.0 billion for Q3 2025, versus -$1.9 billion for Q2 2025 and -$1.8 billion for Q1 2025.